Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: manny t who wrote (9990)	1/12/2004 11:43:07 PM
From: Jane4IceCream	Respond to of 52153

Crossy thinks GORX is going to $20 intermediate term. I'll be happy with $10. Jane

To: manny t who wrote (9990)	1/13/2004 9:26:50 AM
From: Biomaven	Respond to of 52153

<GORX> I don't follow the company at all (in fact never heard of it before today). Thyroid replacement therapy is a very murky and tough field. There is very little switching among brands as many feel the different brands are not bio-equivalent. There is also the murky issue of FDA approval - for many years the leading drugs had no FDA approval until the FDA finally cracked down. Forest was forced to withdraw their offering last year (because they failed to gain approval) and replace it with a "new FDA-approved formula" they licensed from someone else - sounds like a new version of a breakfast cereal. A new patent is still very early in the process - my guess is these guys are a long way from making an impact in this area even if their new process is in fact better. Selling against the big guys is unlikely to work well here, and persuading an existing manufacturer to change their existing process is always hard. Peter